BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15596190)

  • 1. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
    Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
    BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
    Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
    Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
    Gann PH; Ma J; Catalona WJ; Stampfer MJ
    J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
    Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
    Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.